Pediatrix Medical Group (MD) Financials

$23.60 -0.38 (-1.58%)

As of 01:30 PM Eastern

Annual Income Statements for Pediatrix Medical Group

This table shows Pediatrix Medical Group's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	336	325	320	269	-1,498	-796	131	66	-59	-99	167
Consolidated Net Income / (Loss)	336	325	320	269	-1,498	-796	131	66	-60	-99	165
Net Income / (Loss) Continuing Operations	336	325	305	122	42	-9.58	108	63	-60	-99	165
Total Pre-Tax Income	540	514	386	166	59	7.15	135	81	-48	-101	216
Total Operating Income	558	572	455	248	172	98	203	173	7.32	-69	209
Total Gross Profit	2,780	3,183	3,253	1,723	1,780	1,734	1,911	1,972	1,995	2,013	1,914
Total Revenue	2,780	3,183	3,253	1,723	1,780	1,734	1,911	1,972	1,995	2,013	1,914
Operating Revenue	2,780	3,183	3,253	1,723	1,780	1,734	1,911	1,972	1,995	2,013	1,914
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	2,222	2,611	2,798	1,475	1,608	1,636	1,723	1,799	1,987	2,082	1,705
Selling, General & Admin Expense	2,059	2,404	2,613	1,358	1,425	1,443	1,561	1,615	1,676	1,679	1,582
Depreciation Expense	64	89	79	24	26	28	32	36	36	32	22
Other Operating Expenses / (Income)	98	118	106	92	96	91	100	122	125	127	79
Impairment Charge	-	-	0.00	-	-	-	0.00	0.00	148	178	0.00
Restructuring Charge	-	-	0.00	0.00	61	74	22	27	2.22	64	22
Total Other Income / (Expense), net	-18	-58	-69	-82	-113	-91	-68	-91	-56	-33	7.62
Interest Expense	23	63	75	93	119	110	83	97	42	41	36
Interest & Investment Income	4.97	5.20	5.34	11	5.96	19	16	5.39	6.40	8.12	44
Other Income / (Expense), net	-	-	-	-	0.00	-	0.00	0.00	-20	0.00	0.00
Income Tax Expense	204	189	80	45	17	17	27	19	12	-2.27	51
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	-	-	-	-	-	-	2.21	-	-1.52	-	-1.68
Basic Earnings per Share	$3.61	$3.52	$3.47	$2.95	($17.94)	($9.55)	$1.54	$0.79	($0.73)	($1.19)	$1.97
Weighted Average Basic Shares Outstanding	93.08M	92.42M	92.43M	91.10M	83.50M	83.40M	84.83M	83.47M	82.20M	83.33M	84.08M
Diluted Earnings per Share	$3.58	$3.49	$3.45	$2.93	($17.83)	($9.55)	$1.53	$0.79	($0.73)	($1.19)	$1.94
Weighted Average Diluted Shares Outstanding	93.96M	93.11M	92.96M	91.61M	84.01M	83.40M	85.83M	84.12M	82.20M	83.33M	85.27M
Weighted Average Basic & Diluted Shares Outstanding	93.20M	93.79M	92.30M	91.10M	84.28M	85.63M	86.47M	83.03M	84.12M	85.83M	83.00M

This table shows Pediatrix Medical Group's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	21	-125	4.10	-153	19	28	21	39	72	34	30
Consolidated Net Income / (Loss)	21	-124	4.04	-153	19	30	21	39	72	34	30
Net Income / (Loss) Continuing Operations	21	-124	4.04	-153	19	30	21	39	72	34	30
Total Pre-Tax Income	31	-139	7.82	-168	25	33	28	55	88	46	39
Total Operating Income	40	-111	16	-158	34	39	32	60	68	49	42
Total Gross Profit	507	496	495	504	511	502	458	469	493	494	476
Total Revenue	507	496	495	504	511	502	458	469	493	494	476
Operating Revenue	507	496	495	504	511	502	458	469	493	494	476
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	466	608	479	662	477	463	426	409	425	445	435
Selling, General & Admin Expense	426	417	429	414	423	413	396	379	393	414	406
Depreciation Expense	9.21	9.06	10	8.79	6.25	6.87	5.33	5.31	5.55	5.63	6.12
Other Operating Expenses / (Income)	31	32	31	43	29	24	19	21	20	20	17
Impairment Charge	0.00	-	-	182	0.00	-	0.00	0.00	0.00	-	0.00
Restructuring Charge	0.00	2.22	8.48	14	19	24	6.61	3.83	5.95	5.88	4.92
Total Other Income / (Expense), net	-9.44	-27	-8.07	-10	-8.65	-5.96	-4.01	-4.90	20	-3.20	-2.81
Interest Expense	10	10	11	10	10	9.71	9.15	9.13	8.94	8.74	8.27
Interest & Investment Income	0.93	2.72	2.53	0.30	1.53	3.75	5.14	4.23	29	5.54	5.45
Income Tax Expense	9.44	-15	3.79	-15	5.79	2.85	7.35	16	16	12	9.27
Basic Earnings per Share	$0.26	($1.50)	$0.05	($1.84)	$0.23	$0.37	$0.25	$0.46	$0.85	$0.41	$0.37
Weighted Average Basic Shares Outstanding	82.54M	82.20M	82.86M	83.33M	83.89M	83.33M	84.44M	84.80M	84.61M	84.08M	80.88M
Diluted Earnings per Share	$0.26	($1.50)	$0.05	($1.84)	$0.23	$0.37	$0.24	$0.46	$0.84	$0.40	$0.36
Weighted Average Diluted Shares Outstanding	82.95M	82.20M	83.28M	83.33M	84.52M	83.33M	85.43M	85.53M	85.61M	85.27M	83.08M
Weighted Average Basic & Diluted Shares Outstanding	84.02M	84.12M	84.15M	85.87M	85.88M	85.83M	85.91M	87.08M	85.88M	83.00M	82.12M

This table details how cash moves in and out of Pediatrix Medical Group's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	3.64	4.13	25	0.33	161	1,016	-736	-378	63	157	145
Net Cash From Operating Activities	369	444	511	314	358	205	77	167	137	207	271
Net Cash From Continuing Operating Activities	369	444	483	59	74	154	114	182	146	217	275
Net Income / (Loss) Continuing Operations	336	325	305	122	42	-9.58	108	63	-60	-99	165
Consolidated Net Income / (Loss)	336	325	320	269	-1,498	-796	131	66	-60	-99	165
Net Income / (Loss) Discontinued Operations	-	-	15	147	-1,540	-787	23	3.77	0.00	0.00	0.00
Depreciation Expense	64	89	79	24	26	28	32	36	36	32	22
Amortization Expense	1.54	4.82	5.51	4.57	5.67	7.16	4.34	1.77	1.24	0.95	0.94
Non-Cash Adjustments To Reconcile Net Income	31	31	51	34	40	39	38	73	177	197	-7.42
Changes in Operating Assets and Liabilities, net	-64	-5.66	42	-125	-40	89	-55	9.06	-8.39	86	94
Net Cash From Discontinued Operating Activities	-	-	28	255	284	51	-37	-15	-8.76	-11	-3.65
Net Cash From Investing Activities	-848	-821	-577	-143	102	816	-53	-57	-48	-35	-18
Net Cash From Continuing Investing Activities	-848	-821	-553	-85	-50	-58	-55	-57	-48	-35	-18
Purchase of Property, Plant & Equipment	-27	-39	-26	-17	-19	-29	-32	-30	-33	-22	-18
Acquisitions	-819	-762	-531	-65	47	-2.23	-30	-28	-6.67	-8.17	-23
Purchase of Investments	-34	-61	-28	-16	-35	-62	-35	-17	-32	-65	-30
Divestitures	-	0.00	0.00	0.00	-	-	-	-	0.00	0.00	30
Sale and/or Maturity of Investments	32	41	25	14	51	33	16	17	23	52	27
Other Investing Activities, net	0.00	0.00	6.71	-	0.00	-	-	-	0.81	6.84	-3.47
Net Cash From Financing Activities	483	382	90	-171	-393	-4.16	-760	-488	-26	-14	-107
Net Cash From Continuing Financing Activities	483	382	90	-169	-384	-2.91	-760	0.00	0.00	0.00	0.00
Repayment of Debt	-2,172	-1,512	-2,704	-2,102	-1,996	-528	-759	-1,882	-495	-248	-0.06
Repurchase of Common Equity	-235	-62	-70	-302	-145	-8.49	-4.72	-89	-0.92	-1.70	-87
Issuance of Debt	2,872	1,940	2,846	2,224	1,747	528	0.00	1,480	470	236	0.00
Issuance of Common Equity	20	22	24	16	11	7.25	6.85	5.40	4.91	3.64	3.18
Other Financing Activities, net	-1.27	-6.50	-5.45	-5.26	-1.39	-1.16	-3.00	-2.92	-4.44	-4.06	-24
Net Cash From Discontinued Financing Activities	-	-	-0.61	-1.36	-8.96	-1.25	0.00	0.00	0.00	0.00	0.00
Cash Interest Paid	20	60	74	83	95	110	87	116	42	40	34

This table details how cash moves in and out of Pediatrix Medical Group's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	15	52	-65	11	84	126	-131	126	115	35	-169
Net Cash From Operating Activities	80	69	-125	107	92	133	-117	137	137	114	-130
Net Cash From Continuing Operating Activities	81	73	-123	109	96	135	-116	138	138	115	-130
Net Income / (Loss) Continuing Operations	21	-124	4.04	-153	19	30	21	39	72	34	30
Consolidated Net Income / (Loss)	21	-124	4.04	-153	19	30	21	39	72	34	30
Depreciation Expense	9.21	9.06	10	8.79	6.25	6.87	5.33	5.31	5.55	5.63	6.12
Amortization Expense	0.28	0.22	0.20	0.24	0.26	0.25	0.23	0.23	0.24	0.24	0.10
Non-Cash Adjustments To Reconcile Net Income	2.46	170	1.80	194	3.84	-3.06	2.88	3.17	-18	4.17	3.99
Changes in Operating Assets and Liabilities, net	48	18	-139	59	66	100	-145	90	78	71	-169
Net Cash From Discontinued Operating Activities	-1.18	-3.75	-2.60	-2.39	-3.89	-1.80	-1.35	-0.96	-0.83	-0.50	-0.35
Net Cash From Investing Activities	-14	-12	-16	-13	-4.34	-1.94	-7.46	-7.15	6.60	-10	-12
Net Cash From Continuing Investing Activities	-14	-12	-16	-29	-4.34	-1.94	-7.46	-7.15	6.60	-10	-12
Purchase of Property, Plant & Equipment	-9.15	-9.04	-5.33	-6.96	-6.29	-3.44	-3.32	-4.52	-5.34	-5.29	-6.25
Acquisitions	-	-5.00	-8.17	-	-	-	0.00	-	-19	-4.00	-7.00
Purchase of Investments	-8.72	-5.42	-17	-23	-14	-10	-7.76	-14	-1.96	-6.37	-7.01
Sale and/or Maturity of Investments	3.75	6.35	14	17	14	7.17	7.30	11	3.04	5.25	7.75
Other Investing Activities, net	-	-	0.00	-	-	-	-3.69	0.05	0.05	0.12	0.53
Net Cash From Financing Activities	-51	-4.75	76	-83	-3.07	-4.96	-6.04	-4.26	-29	-69	-28
Net Cash From Continuing Financing Activities	-51	21	76	-83	-3.07	9.52	-6.04	-4.26	-29	39	-28
Repayment of Debt	-100	-3.45	-94	-148	6.22	-12	-0.10	-4.72	9.35	0.10	-6.25
Repurchase of Common Equity	-0.13	-	-0.89	-0.01	-0.16	-0.64	-1.57	-0.21	-21	-64	-21
Issuance of Debt	49	-	171	65	-	-	0.00	-	-	-	0.00
Issuance of Common Equity	1.19	1.04	0.86	1.15	0.90	0.73	0.66	1.18	0.70	0.65	0.54
Other Financing Activities, net	-0.70	-2.33	-0.69	-0.70	-10	7.37	-5.03	-0.51	-18	-5.34	-0.48

This table presents Pediatrix Medical Group's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	4,547	5,339	5,867	5,937	4,146	3,348	2,723	2,348	2,220	2,153	2,247
Total Current Assets	528	587	627	660	732	1,549	841	428	483	640	764
Cash & Equivalents	52	56	60	25	108	1,124	387	9.82	73	230	375
Short-Term Investments	8.85	11	10	22	75	105	100	93	104	119	124
Accounts Receivable	445	495	504	507	434	242	302	297	272	260	230
Prepaid Expenses	9.64	11	16	17	17	17	19	15	14	13	13
Current Deferred & Refundable Income Taxes	-	-	-	-	-	0.00	14	0.00	7.57	13	13
Other Current Assets	13	14	37	17	12	62	19	13	12	5.09	8.88
Plant, Property, & Equipment, net	84	103	124	90	73	76	70	73	76	39	39
Total Noncurrent Assets	3,936	4,649	5,117	5,187	3,342	1,722	1,812	1,847	1,661	1,474	1,444
Goodwill	3,366	3,845	4,284	4,061	1,480	1,478	1,505	1,532	1,384	1,243	1,261
Intangible Assets	424	669	640	313	29	27	22	18	21	12	17
Noncurrent Deferred & Refundable Income Taxes	-	-	-	22	87	54	88	106	103	104	74
Other Noncurrent Operating Assets	82	57	112	81	105	163	196	190	152	116	92
Total Liabilities & Shareholders' Equity	4,547	5,339	5,867	5,937	4,146	3,348	2,723	2,348	2,220	2,153	2,247
Total Liabilities	2,109	2,579	2,801	2,850	2,647	2,600	1,826	1,456	1,371	1,388	1,381
Total Current Liabilities	429	449	531	503	542	444	427	427	389	434	459
Short-Term Debt	12	22	1.40	0.25	-	-	2.49	15	15	21	27
Accounts Payable	396	408	438	449	411	423	394	374	351	399	420
Current Deferred & Payable Income Tax Liabilities	21	19	92	31	6.04	0.00	11	16	2.16	2.17	0.98
Other Current Liabilities	-	-	-	0.00	18	21	20	22	21	13	12
Total Noncurrent Liabilities	1,681	2,130	2,269	2,347	2,105	2,156	1,398	1,029	982	954	922
Long-Term Debt	1,263	1,684	1,851	1,974	1,730	1,743	0.00	636	618	597	571
Noncurrent Deferred & Payable Income Tax Liabilities	189	228	148	96	56	62	41	34	34	34	57
Other Noncurrent Operating Liabilities	229	218	270	241	272	352	1,357	359	329	322	294
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	2,438	2,761	3,066	3,088	1,499	748	897	892	849	765	866
Total Preferred & Common Equity	2,438	2,761	3,066	3,088	1,499	747	896	892	849	765	866
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	2,438	2,761	3,066	3,088	1,499	747	896	892	849	765	866
Common Stock	927	975	1,018	994	989	1,030	1,051	984	1,001	1,015	948
Retained Earnings	1,510	1,786	2,048	2,094	510	-286	-155	-89	-149	-249	-83
Accumulated Other Comprehensive Income / (Loss)	-	-	-	-	0.08	3.53	1.32	-3.74	-2.21	-1.07	0.61

This table presents Pediatrix Medical Group's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	2,332	2,320	2,306	2,326	2,168	1,995	2,077	1,993	2,102	2,199	2,070
Total Current Assets	424	409	398	421	427	429	528	492	613	717	587
Cash & Equivalents	8.67	6.12	5.85	21	8.00	19	104	99	225	340	206
Short-Term Investments	91	97	98	104	107	114	117	120	124	123	123
Accounts Receivable	294	279	271	277	284	274	287	243	239	231	225
Prepaid Expenses	9.66	15	12	11	13	12	10	12	10	8.94	13
Current Deferred & Refundable Income Taxes	9.73	-	-	-	5.19	0.00	1.20	10	7.63	3.82	12
Other Current Assets	9.90	12	10	7.87	9.58	9.94	9.48	7.61	7.68	10	8.21
Plant, Property, & Equipment, net	72	73	73	75	74	48	42	38	39	39	41
Total Noncurrent Assets	1,837	1,839	1,834	1,831	1,667	1,518	1,507	1,464	1,450	1,444	1,442
Noncurrent Note & Lease Receivables	-	67	-	-	70	-	-	40	-	-	37
Goodwill	1,532	1,532	1,532	1,532	1,393	1,239	1,239	1,243	1,243	1,255	1,268
Intangible Assets	20	17	17	15	19	10	13	10	9.30	15	16
Noncurrent Deferred & Refundable Income Taxes	98	103	102	103	102	124	119	99	89	80	66
Other Noncurrent Operating Assets	187	119	184	180	83	145	135	71	109	94	55
Total Liabilities & Shareholders' Equity	2,332	2,320	2,306	2,326	2,168	1,995	2,077	1,993	2,102	2,199	2,070
Total Liabilities	1,473	1,410	1,363	1,358	1,312	1,289	1,344	1,204	1,268	1,309	1,192
Total Current Liabilities	352	284	320	350	247	310	373	271	341	393	443
Short-Term Debt	15	15	15	15	16	18	19	22	24	25	192
Accounts Payable	306	227	278	303	207	267	333	234	303	352	237
Current Deferred & Payable Income Tax Liabilities	7.66	22	6.15	11	2.80	6.33	3.32	2.58	1.95	2.75	1.40
Other Current Liabilities	23	21	22	22	21	19	17	12	12	12	12
Total Noncurrent Liabilities	1,122	1,126	1,043	1,008	1,065	979	971	933	927	916	749
Long-Term Debt	731	114	666	622	80	0.00	0.00	590	584	577	398
Noncurrent Deferred & Payable Income Tax Liabilities	40	33	38	41	34	31	36	34	36	38	57
Other Noncurrent Operating Liabilities	351	979	339	345	951	948	936	308	307	301	294
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	859	910	942	968	856	706	732	789	834	891	879
Total Preferred & Common Equity	859	910	942	968	856	706	732	789	834	891	879
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	859	910	942	968	856	706	732	789	834	891	879
Common Stock	981	988	992	997	1,004	1,007	1,012	1,017	1,022	1,007	932
Retained Earnings	-119	-75	-47	-25	-145	-298	-279	-228	-189	-117	-54
Accumulated Other Comprehensive Income / (Loss)	-4.10	-3.13	-3.52	-3.52	-2.15	-1.95	-0.21	-0.29	0.14	0.45	0.08

This table displays calculated financial ratios and metrics derived from Pediatrix Medical Group's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	13.99%	14.50%	2.21%	-47.04%	3.29%	-2.57%	10.22%	3.18%	1.15%	0.92%	-4.92%
EBITDA Growth	11.32%	6.76%	-19.00%	-48.58%	-26.67%	-34.24%	79.01%	-12.24%	-88.23%	-243.68%	751.72%
EBIT Growth	8.75%	2.48%	-20.43%	-45.40%	-30.85%	-42.87%	106.78%	-14.90%	-107.34%	-441.94%	403.89%
NOPAT Growth	8.45%	4.09%	-0.25%	-49.59%	-32.09%	-206.65%	223.21%	-18.06%	-96.14%	-1,038.57%	431.74%
Net Income Growth	5.83%	-3.31%	-1.30%	-16.15%	-657.54%	46.82%	116.44%	-49.34%	-191.07%	-64.00%	266.94%
EPS Growth	12.58%	-2.51%	-1.15%	-15.07%	-708.53%	46.44%	116.02%	-48.37%	-192.41%	-63.01%	263.03%
Operating Cash Flow Growth	-12.76%	20.36%	15.23%	-38.65%	14.03%	-42.80%	-62.50%	117.55%	-17.74%	50.43%	31.23%
Free Cash Flow Firm Growth	-333.50%	29.51%	76.42%	851.15%	348.77%	-97.31%	1,178.17%	-188.48%	115.68%	58.53%	3.48%
Invested Capital Growth	32.12%	20.39%	10.36%	-9.95%	-65.71%	-14.31%	-67.34%	249.41%	-9.39%	-20.74%	-6.83%
Revenue Q/Q Growth	3.39%	2.88%	-3.70%	-47.34%	73.79%	41.00%	4.48%	0.78%	-0.86%	0.30%	-0.45%
EBITDA Q/Q Growth	2.58%	-0.10%	-10.67%	-44.13%	114.35%	58.31%	16.32%	-12.89%	-87.15%	80.70%	3.69%
EBIT Q/Q Growth	1.80%	-1.41%	-8.50%	-41.80%	58.25%	91.77%	21.35%	-15.62%	-108.19%	68.69%	4.77%
NOPAT Q/Q Growth	2.09%	-2.64%	18.80%	-52.48%	62.32%	-467.16%	23.58%	-11.90%	-95.54%	68.69%	0.78%
Net Income Q/Q Growth	1.25%	-4.23%	22.12%	-22.03%	-3.52%	-10.19%	584.42%	-21.21%	-164.58%	60.97%	1.97%
EPS Q/Q Growth	0.28%	-4.90%	22.34%	-21.02%	-2.59%	-12.22%	800.00%	-20.20%	-165.18%	25.63%	1.57%
Operating Cash Flow Q/Q Growth	-16.84%	6.43%	14.48%	-12.36%	-4.30%	-41.83%	271.88%	48.40%	-17.65%	44.65%	-6.52%
Free Cash Flow Firm Q/Q Growth	8.64%	1.18%	-660.18%	489.25%	52.66%	-97.74%	244.09%	7.21%	0.48%	-72.02%	167.62%
Invested Capital Q/Q Growth	0.59%	0.16%	3.62%	-11.88%	-51.24%	384.20%	5.86%	-4.30%	-11.84%	94.63%	-6.47%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	22.43%	20.92%	16.58%	16.09%	11.43%	7.71%	12.53%	10.65%	1.24%	-1.77%	12.10%
Operating Margin	20.07%	17.96%	13.98%	14.42%	9.65%	5.66%	10.62%	8.76%	0.37%	-3.41%	10.91%
EBIT Margin	20.07%	17.96%	13.98%	14.42%	9.65%	5.66%	10.62%	8.76%	-0.64%	-3.41%	10.91%
Profit (Net Income) Margin	12.08%	10.20%	9.85%	15.59%	-84.15%	-45.93%	6.85%	3.36%	-3.03%	-4.92%	8.64%
Tax Burden Percent	62.20%	63.18%	83.07%	161.62%	-2,547.81%	-11,142.81%	96.83%	81.52%	124.92%	97.76%	76.42%
Interest Burden Percent	96.75%	89.87%	84.78%	66.91%	34.23%	7.28%	66.64%	47.12%	381.41%	147.48%	103.65%
Effective Tax Rate	37.80%	36.82%	20.80%	26.89%	28.20%	234.02%	20.14%	23.11%	0.00%	0.00%	23.58%
Return on Invested Capital (ROIC)	11.01%	9.13%	7.93%	4.01%	4.28%	-9.62%	19.36%	14.34%	0.37%	-4.11%	15.98%
ROIC Less NNEP Spread (ROIC-NNEP)	9.60%	6.43%	5.48%	10.00%	-270.72%	-282.64%	-193.26%	-194.61%	-12.68%	-18.18%	19.15%
Return on Net Nonoperating Assets (RNNOA)	3.27%	3.36%	3.07%	4.72%	-69.58%	-61.28%	-3.44%	-6.92%	-7.31%	-8.16%	4.31%
Return on Equity (ROE)	14.27%	12.49%	11.00%	8.73%	-65.30%	-70.90%	15.93%	7.42%	-6.94%	-12.28%	20.28%
Cash Return on Invested Capital (CROIC)	-16.67%	-9.37%	-1.92%	14.48%	102.14%	5.79%	120.88%	-96.66%	10.23%	19.02%	23.05%
Operating Return on Assets (OROA)	13.68%	11.56%	8.12%	4.21%	3.41%	2.62%	6.69%	6.81%	-0.56%	-3.14%	9.49%
Return on Assets (ROA)	8.23%	6.57%	5.72%	4.55%	-29.71%	-21.26%	4.31%	2.62%	-2.65%	-4.53%	7.52%
Return on Common Equity (ROCE)	14.27%	12.49%	11.00%	8.73%	-65.30%	-70.90%	15.92%	7.42%	-6.94%	-12.28%	20.28%
Return on Equity Simple (ROE_SIMPLE)	13.77%	11.76%	10.45%	8.70%	-99.91%	-106.56%	14.61%	7.44%	-7.11%	-12.95%	0.00%
Net Operating Profit after Tax (NOPAT)	347	361	360	182	123	-132	162	133	5.12	-48	160
NOPAT Margin	12.48%	11.35%	11.07%	10.54%	6.93%	-7.59%	8.48%	6.73%	0.26%	-2.39%	8.34%
Net Nonoperating Expense Percent (NNEP)	1.41%	2.70%	2.45%	-5.99%	275.00%	273.02%	212.63%	208.95%	13.06%	14.07%	-3.17%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	8.61%	0.35%	-3.48%	10.91%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	74.08%	75.52%	80.32%	78.80%	80.08%	83.21%	81.67%	81.88%	84.02%	83.42%	82.64%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	79.93%	82.04%	86.02%	85.58%	90.35%	94.34%	90.14%	91.24%	99.63%	103.41%	89.09%
Earnings before Interest and Taxes (EBIT)	558	572	455	248	172	98	203	173	-13	-69	209
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	624	666	539	277	203	134	239	210	25	-36	232
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.76	2.26	1.63	0.96	1.56	2.81	2.62	1.38	0.92	1.47	2.12
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.42	1.96	1.54	1.71	1.32	1.21	1.23	0.63	0.39	0.56	0.96
Price to Earnings (P/E)	20.04	19.21	15.62	10.98	0.00	0.00	17.96	18.61	0.00	0.00	11.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	4.99%	5.21%	6.40%	9.10%	0.00%	0.00%	5.57%	5.37%	0.00%	0.00%	9.10%
Enterprise Value to Invested Capital (EV/IC)	2.20	1.81	1.41	1.12	2.64	2.07	4.53	1.24	0.95	1.35	2.01
Enterprise Value to Revenue (EV/Rev)	2.84	2.45	2.06	2.78	2.19	1.51	0.98	0.90	0.62	0.69	1.01
Enterprise Value to EBITDA (EV/EBITDA)	12.65	11.72	12.44	17.27	19.13	19.55	7.80	8.49	50.02	0.00	8.35
Enterprise Value to EBIT (EV/EBIT)	14.14	13.65	14.74	19.28	22.65	26.64	9.21	10.32	0.00	0.00	9.26
Enterprise Value to NOPAT (EV/NOPAT)	22.74	21.60	18.62	26.37	31.55	0.00	11.53	13.43	241.38	0.00	12.12
Enterprise Value to Operating Cash Flow (EV/OCF)	21.40	17.58	13.11	15.26	10.88	12.78	24.34	10.68	9.01	6.76	7.14
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	7.30	1.32	33.04	1.85	0.00	8.82	6.28	8.40
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.52	0.62	0.60	0.64	1.15	2.33	0.00	0.73	0.75	0.81	0.69
Long-Term Debt to Equity	0.52	0.61	0.60	0.64	1.15	2.33	0.00	0.71	0.73	0.78	0.66
Financial Leverage	0.34	0.52	0.56	0.47	0.26	0.22	0.02	0.04	0.58	0.45	0.22
Leverage Ratio	1.73	1.90	1.92	1.92	2.20	3.34	3.69	2.84	2.62	2.71	2.70
Compound Leverage Factor	1.68	1.71	1.63	1.28	0.75	0.24	2.46	1.34	10.01	4.00	2.80
Debt to Total Capital	34.34%	38.19%	37.66%	39.00%	53.58%	69.97%	0.28%	42.21%	42.72%	44.67%	40.82%
Short-Term Debt to Total Capital	0.32%	0.49%	0.03%	0.01%	0.00%	0.00%	0.28%	0.97%	1.01%	1.49%	1.83%
Long-Term Debt to Total Capital	34.01%	37.70%	37.64%	39.00%	53.58%	69.97%	0.00%	41.25%	41.72%	43.19%	38.99%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.01%	0.00%	0.00%	0.00%	0.00%	0.01%	0.02%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	65.66%	61.81%	62.34%	61.00%	46.42%	30.02%	99.70%	57.79%	57.28%	55.33%	59.18%
Debt to EBITDA	2.04	2.56	3.44	7.12	8.51	13.03	0.01	3.10	25.61	-17.38	2.58
Net Debt to EBITDA	1.85	2.34	3.16	6.63	7.61	3.84	-2.02	2.61	18.42	-7.57	0.42
Long-Term Debt to EBITDA	2.02	2.53	3.43	7.12	8.51	13.03	0.00	3.03	25.01	-16.80	2.46
Debt to NOPAT	3.67	4.72	5.14	10.87	14.03	-13.25	0.02	4.91	123.58	-12.84	3.74
Net Debt to NOPAT	3.32	4.32	4.72	10.12	12.55	-3.91	-2.99	4.13	88.90	-5.60	0.61
Long-Term Debt to NOPAT	3.64	4.66	5.14	10.87	14.03	-13.25	0.00	4.79	120.67	-12.41	3.58
Altman Z-Score	3.42	2.90	2.39	1.58	1.32	1.38	1.82	1.54	1.18	1.27	2.07
Noncontrolling Interest Sharing Ratio	0.03%	0.01%	0.00%	0.00%	0.00%	0.01%	0.03%	0.01%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.23	1.31	1.18	1.31	1.35	3.49	1.97	1.00	1.24	1.47	1.66
Quick Ratio	1.18	1.25	1.08	1.10	1.14	3.31	1.85	0.94	1.16	1.40	1.59
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-526	-370	-87	656	2,945	79	1,012	-895	140	222	230
Operating Cash Flow to CapEx	1,361.88%	1,130.24%	1,955.56%	1,832.41%	1,856.41%	738.49%	1,106.20%	589.27%	422.27%	1,360.20%	1,468.69%
Free Cash Flow to Firm to Interest Expense	-22.74	-5.87	-1.17	7.06	24.76	0.72	12.15	-9.25	3.34	5.46	6.40
Operating Cash Flow to Interest Expense	15.95	7.03	6.86	3.38	3.01	1.85	0.92	1.73	3.26	5.07	7.54
Operating Cash Flow Less CapEx to Interest Expense	14.78	6.41	6.51	3.19	2.85	1.60	0.84	1.43	2.49	4.70	7.02
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.68	0.64	0.58	0.29	0.35	0.46	0.63	0.78	0.87	0.92	0.87
Accounts Receivable Turnover	6.98	6.77	6.51	3.41	3.78	5.13	7.03	6.59	7.01	7.56	7.82
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	37.15	34.10	28.71	16.11	21.82	23.30	26.12	27.50	26.79	35.06	48.85
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	52.32	53.89	56.05	107.05	96.49	71.17	51.92	55.39	52.07	48.26	46.69
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	52.32	53.89	56.05	107.05	96.49	71.17	51.92	55.39	52.07	48.26	46.69
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	3,589	4,320	4,768	4,294	1,472	1,262	412	1,440	1,305	1,034	963
Invested Capital Turnover	0.88	0.80	0.72	0.38	0.62	1.27	2.28	2.13	1.45	1.72	1.92
Increase / (Decrease) in Invested Capital	873	732	448	-475	-2,821	-211	-850	1,028	-135	-271	-71
Enterprise Value (EV)	7,890	7,802	6,707	4,788	3,891	2,615	1,868	1,783	1,237	1,396	1,935
Market Capitalization	6,739	6,242	5,005	2,951	2,343	2,101	2,352	1,234	781	1,127	1,837
Book Value per Share	$25.92	$29.48	$32.74	$34.53	$17.78	$8.73	$10.37	$10.73	$10.11	$8.91	$10.08
Tangible Book Value per Share	($14.39)	($18.72)	($19.83)	($14.39)	($0.11)	($8.85)	($7.29)	($7.93)	($6.62)	($5.70)	($4.79)
Total Capital	3,713	4,466	4,919	5,062	3,229	2,490	899	1,543	1,482	1,383	1,463
Total Debt	1,275	1,706	1,853	1,975	1,730	1,743	2.49	651	633	618	597
Total Long-Term Debt	1,263	1,684	1,851	1,974	1,730	1,743	0.00	636	618	597	571
Net Debt	1,151	1,560	1,702	1,837	1,548	514	-485	548	456	269	98
Capital Expenditures (CapEx)	27	39	26	17	19	28	6.94	28	33	15	18
Debt-free, Cash-free Net Working Capital (DFCFNWC)	50	93	27	90	7.31	-124	-71	-87	-68	-122	-168
Debt-free Net Working Capital (DFNWC)	111	160	97	157	190	1,105	416	16	109	226	331
Net Working Capital (NWC)	99	138	96	157	190	1,105	413	1.01	95	205	305
Net Nonoperating Expense (NNE)	11	37	40	-87	1,621	665	31	66	66	51	-5.82
Net Nonoperating Obligations (NNO)	1,151	1,560	1,702	1,206	-27	514	-485	548	456	269	98
Total Depreciation and Amortization (D&A)	66	94	84	29	32	36	36	37	37	33	23
Debt-free, Cash-free Net Working Capital to Revenue	1.82%	2.93%	0.82%	5.23%	0.41%	-7.13%	-3.74%	-4.42%	-3.43%	-6.08%	-8.79%
Debt-free Net Working Capital to Revenue	3.99%	5.03%	2.99%	9.14%	10.66%	63.73%	21.75%	0.81%	5.49%	11.23%	17.32%
Net Working Capital to Revenue	3.56%	4.34%	2.94%	9.12%	10.66%	63.73%	21.62%	0.05%	4.74%	10.21%	15.92%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$3.61	$3.52	$3.47	$2.95	($17.94)	$0.00	$1.54	$0.79	$0.73	($1.19)	$1.97
Adjusted Weighted Average Basic Shares Outstanding	93.08M	92.42M	92.43M	91.10M	83.50M	0.00	84.83M	83.47M	82.20M	83.33M	84.08M
Adjusted Diluted Earnings per Share	$3.58	$3.49	$3.45	$2.93	($17.94)	$0.00	$1.53	$0.79	$0.73	($1.19)	$1.94
Adjusted Weighted Average Diluted Shares Outstanding	93.96M	93.11M	92.96M	91.61M	83.50M	0.00	85.83M	84.12M	82.20M	83.33M	85.27M
Adjusted Basic & Diluted Earnings per Share	$3.61	$3.52	$3.47	$2.95	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	93.80M	93.79M	93.80M	87.92M	84.28M	0.00	86.47M	83.03M	84.12M	85.83M	83.00M
Normalized Net Operating Profit after Tax (NOPAT)	347	361	360	182	167	120	186	154	110	122	177
Normalized NOPAT Margin	12.48%	11.35%	11.07%	10.54%	9.39%	6.94%	9.71%	7.80%	5.54%	6.05%	9.23%
Pre Tax Income Margin	19.41%	16.14%	11.85%	9.65%	3.30%	0.41%	7.08%	4.13%	-2.42%	-5.03%	11.31%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	24.14	9.06	6.10	2.67	1.44	0.89	2.44	1.79	-0.30	-1.69	5.81
NOPAT to Interest Expense	15.01	5.72	4.83	1.95	1.04	-1.19	1.95	1.37	0.12	-1.18	4.44
EBIT Less CapEx to Interest Expense	22.97	8.44	5.75	2.49	1.28	0.64	2.35	1.49	-1.07	-2.06	5.29
NOPAT Less CapEx to Interest Expense	13.84	5.10	4.48	1.77	0.87	-1.44	1.86	1.08	-0.65	-1.55	3.92
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	70.02%	19.05%	21.91%	112.48%	-9.70%	-1.07%	3.60%	133.44%	-1.52%	-1.72%	52.41%

This table displays calculated financial ratios and metrics derived from Pediatrix Medical Group's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	83,001,072.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	83,001,072.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	0.36
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	3.41%	-3.39%	0.83%	0.74%	0.90%	1.19%	-7.42%	-7.03%	-3.58%	-1.71%	3.89%
EBITDA Growth	-12.43%	-324.17%	-32.97%	-357.33%	-18.93%	145.41%	42.66%	143.99%	83.30%	17.77%	27.12%
EBIT Growth	-15.01%	-409.37%	-47.10%	-425.22%	-16.00%	135.24%	101.99%	137.96%	101.53%	24.19%	29.77%
NOPAT Growth	-20.47%	-351.06%	-60.22%	-413.50%	-6.73%	146.04%	189.15%	138.73%	113.32%	0.31%	33.82%
Net Income Growth	-30.39%	-519.05%	-71.60%	-641.07%	-9.12%	124.52%	413.93%	125.66%	268.85%	10.51%	42.61%
EPS Growth	-29.73%	-528.57%	-70.59%	-641.18%	-11.54%	124.67%	380.00%	125.00%	265.22%	8.11%	50.00%
Operating Cash Flow Growth	-4.07%	-29.83%	-24.09%	20.10%	14.89%	92.07%	6.20%	28.25%	49.49%	-14.22%	-10.54%
Free Cash Flow Firm Growth	104.87%	105.73%	659.68%	1,216.49%	1,753.56%	436.26%	-400.98%	-156.15%	-145.47%	-65.20%	122.98%
Invested Capital Growth	-1.64%	-9.39%	-10.55%	-61.10%	-64.10%	-20.74%	41.27%	84.94%	93.87%	-6.83%	-3.57%
Revenue Q/Q Growth	1.21%	-2.01%	-0.27%	1.86%	1.36%	-1.72%	-8.76%	2.29%	5.13%	0.18%	-3.56%
EBITDA Q/Q Growth	-13.88%	-305.37%	125.83%	-663.23%	127.13%	15.05%	-18.86%	73.67%	12.89%	-25.97%	-12.41%
EBIT Q/Q Growth	-16.96%	-376.84%	114.25%	-1,092.47%	121.45%	16.15%	-18.30%	86.50%	13.67%	-28.30%	-14.63%
NOPAT Q/Q Growth	-20.66%	-379.32%	110.50%	-1,447.10%	123.60%	37.89%	-34.05%	80.43%	30.02%	-35.16%	-12.02%
Net Income Q/Q Growth	-24.37%	-681.02%	103.25%	-3,892.44%	112.70%	56.78%	-31.97%	89.32%	82.65%	-53.03%	-12.21%
EPS Q/Q Growth	-23.53%	-676.92%	103.33%	-3,780.00%	112.50%	60.87%	-35.14%	91.67%	82.61%	-52.38%	-10.00%
Operating Cash Flow Q/Q Growth	-10.24%	-13.37%	-280.83%	185.41%	-14.13%	44.83%	-188.31%	216.77%	0.09%	-16.89%	-213.80%
Free Cash Flow Firm Q/Q Growth	-15.36%	8.69%	87.07%	664.94%	19.17%	-68.55%	-204.99%	-42.71%	3.50%	124.07%	-30.67%
Invested Capital Q/Q Growth	-2.59%	-11.84%	-35.83%	-29.40%	-10.10%	94.63%	14.36%	-7.58%	-5.76%	-6.47%	18.36%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	9.82%	-20.59%	5.33%	-29.49%	7.89%	9.24%	8.22%	13.95%	14.98%	11.07%	10.05%
Operating Margin	7.95%	-22.46%	3.21%	-31.28%	6.62%	7.82%	7.00%	12.77%	13.81%	9.88%	8.75%
EBIT Margin	7.95%	-22.46%	3.21%	-31.28%	6.62%	7.82%	7.00%	12.77%	13.81%	9.88%	8.75%
Profit (Net Income) Margin	4.22%	-25.04%	0.82%	-30.34%	3.80%	6.07%	4.52%	8.37%	14.55%	6.82%	6.21%
Tax Burden Percent	69.38%	89.51%	51.57%	91.23%	77.04%	91.45%	73.82%	71.42%	81.69%	73.87%	76.13%
Interest Burden Percent	76.56%	124.54%	49.23%	106.34%	74.60%	84.82%	87.51%	91.82%	128.99%	93.44%	93.25%
Effective Tax Rate	30.62%	0.00%	48.43%	0.00%	22.96%	8.55%	26.18%	28.58%	18.31%	26.13%	23.87%
Return on Invested Capital (ROIC)	7.44%	-22.85%	3.73%	-41.55%	10.18%	12.31%	10.12%	21.02%	27.77%	13.99%	11.08%
ROIC Less NNEP Spread (ROIC-NNEP)	6.31%	-32.06%	-114.83%	-60.02%	5.91%	10.81%	8.54%	16.15%	-24.40%	12.70%	10.42%
Return on Net Nonoperating Assets (RNNOA)	4.00%	-18.49%	-0.46%	-16.80%	1.08%	4.85%	1.94%	1.51%	0.93%	2.86%	4.09%
Return on Equity (ROE)	11.43%	-41.34%	3.28%	-58.35%	11.26%	17.17%	12.06%	22.53%	28.70%	16.84%	15.17%
Cash Return on Invested Capital (CROIC)	9.36%	10.23%	10.60%	73.84%	79.05%	19.02%	-37.85%	-44.40%	-43.61%	23.05%	18.05%
Operating Return on Assets (OROA)	6.87%	-19.61%	2.86%	-29.12%	6.03%	7.20%	6.65%	12.10%	12.41%	8.60%	8.32%
Return on Assets (ROA)	3.65%	-21.87%	0.73%	-28.26%	3.47%	5.59%	4.30%	7.93%	13.08%	5.94%	5.90%
Return on Common Equity (ROCE)	11.43%	-41.34%	3.28%	-58.35%	11.26%	17.17%	12.06%	22.53%	28.70%	16.84%	15.17%
Return on Equity Simple (ROE_SIMPLE)	9.66%	0.00%	-8.24%	-35.65%	-34.65%	0.00%	-10.44%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	28	-78	8.20	-110	26	36	24	43	56	36	32
NOPAT Margin	5.52%	-15.72%	1.66%	-21.89%	5.10%	7.15%	5.17%	9.12%	11.28%	7.30%	6.66%
Net Nonoperating Expense Percent (NNEP)	1.13%	9.21%	118.56%	18.47%	4.26%	1.50%	1.58%	4.87%	52.18%	1.29%	0.65%
Return On Investment Capital (ROIC_SIMPLE)	-	-5.26%	0.86%	-	-	2.60%	1.69%	2.97%	3.72%	2.46%	2.16%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	84.05%	83.93%	86.72%	82.17%	82.76%	82.12%	86.32%	80.88%	79.76%	83.78%	85.26%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	92.05%	122.46%	96.79%	131.28%	93.38%	92.18%	93.00%	87.23%	86.19%	90.12%	91.25%
Earnings before Interest and Taxes (EBIT)	40	-111	16	-158	34	39	32	60	68	49	42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	50	-102	26	-149	40	46	38	65	74	55	48
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.10	0.92	0.98	0.90	1.36	1.47	1.58	1.48	1.64	2.12	2.02
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.53	0.39	0.42	0.32	0.50	0.56	0.63	0.64	0.76	0.96	0.92
Price to Earnings (P/E)	11.38	0.00	0.00	0.00	0.00	0.00	0.00	11.16	8.95	11.00	10.09
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	8.79%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	8.96%	11.18%	9.10%	9.91%
Enterprise Value to Invested Capital (EV/IC)	1.07	0.95	0.98	0.88	1.49	1.35	1.38	1.37	1.55	2.01	1.79
Enterprise Value to Revenue (EV/Rev)	0.78	0.62	0.41	0.26	0.40	0.69	0.83	0.77	0.83	1.01	1.05
Enterprise Value to EBITDA (EV/EBITDA)	8.20	50.02	25.95	0.00	0.00	0.00	0.00	7.86	7.16	8.35	8.43
Enterprise Value to EBIT (EV/EBIT)	10.20	0.00	0.00	0.00	0.00	0.00	0.00	9.04	8.02	9.26	9.33
Enterprise Value to NOPAT (EV/NOPAT)	13.73	241.38	0.00	0.00	0.00	0.00	0.00	11.64	10.09	12.12	12.17
Enterprise Value to Operating Cash Flow (EV/OCF)	9.47	9.01	7.29	3.97	5.56	6.76	7.64	6.10	5.51	7.14	7.87
Enterprise Value to Free Cash Flow (EV/FCFF)	11.30	8.82	8.77	0.67	1.00	6.28	0.00	0.00	0.00	8.40	9.71
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.66	0.75	0.11	0.03	0.03	0.81	0.78	0.73	0.68	0.69	0.67
Long-Term Debt to Equity	0.64	0.73	0.09	0.00	0.00	0.78	0.75	0.70	0.65	0.66	0.45
Financial Leverage	0.63	0.58	0.00	0.28	0.18	0.45	0.23	0.09	-0.04	0.22	0.39
Leverage Ratio	2.55	2.62	2.54	2.61	2.59	2.71	2.53	2.66	2.63	2.70	2.44
Compound Leverage Factor	1.95	3.27	1.25	2.77	1.93	2.30	2.21	2.44	3.40	2.52	2.27
Debt to Total Capital	39.67%	42.72%	10.12%	2.45%	2.56%	44.67%	43.70%	42.15%	40.35%	40.82%	40.21%
Short-Term Debt to Total Capital	0.93%	1.01%	1.72%	2.45%	2.56%	1.49%	1.58%	1.64%	1.70%	1.83%	13.10%
Long-Term Debt to Total Capital	38.74%	41.72%	8.40%	0.00%	0.00%	43.19%	42.12%	40.51%	38.65%	38.99%	27.11%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	60.33%	57.28%	89.88%	97.55%	97.44%	55.33%	56.30%	57.85%	59.65%	59.18%	59.79%
Debt to EBITDA	3.31	25.61	3.04	-0.10	-0.10	-17.38	-25.24	3.20	2.70	2.58	2.44
Net Debt to EBITDA	2.66	18.42	-0.60	0.66	1.09	-7.57	-16.21	1.37	0.62	0.42	1.08
Long-Term Debt to EBITDA	3.23	25.01	2.52	0.00	0.00	-16.80	-24.33	3.08	2.58	2.46	1.65
Debt to NOPAT	5.54	123.58	-20.17	-0.12	-0.13	-12.84	-16.67	4.74	3.81	3.74	3.53
Net Debt to NOPAT	4.45	88.90	3.99	0.77	1.31	-5.60	-10.70	2.02	0.88	0.61	1.56
Long-Term Debt to NOPAT	5.41	120.67	-16.74	0.00	0.00	-12.41	-16.07	4.56	3.65	3.58	2.38
Altman Z-Score	1.41	1.03	1.34	0.90	1.37	1.44	1.64	1.63	1.75	1.83	1.94
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.20	1.24	1.72	1.38	1.42	1.47	1.81	1.80	1.83	1.66	1.33
Quick Ratio	1.15	1.16	1.61	1.31	1.36	1.40	1.70	1.72	1.77	1.59	1.25
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	53	57	107	818	975	306	-322	-459	-443	107	74
Operating Cash Flow to CapEx	873.26%	829.04%	-2,349.46%	1,536.21%	1,460.06%	0.00%	-3,540.17%	3,038.03%	2,571.84%	2,158.16%	-2,078.55%
Free Cash Flow to Firm to Interest Expense	5.07	5.67	10.09	79.34	96.25	31.56	-35.15	-50.30	-49.57	12.21	8.95
Operating Cash Flow to Interest Expense	7.71	6.87	-11.81	10.38	9.07	13.70	-12.83	15.02	15.35	13.06	-15.71
Operating Cash Flow Less CapEx to Interest Expense	6.82	6.04	-12.32	9.70	8.45	13.80	-13.19	14.53	14.76	12.45	-16.47
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.86	0.87	0.89	0.93	0.91	0.92	0.95	0.95	0.90	0.87	0.95
Accounts Receivable Turnover	7.04	7.01	7.11	7.35	7.11	7.56	7.51	7.56	7.42	7.82	8.27
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	27.41	26.79	27.14	33.04	34.29	35.06	35.11	44.70	47.73	48.85	48.71
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	51.86	52.07	51.36	49.67	51.31	48.26	48.60	48.26	49.18	46.69	44.15
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	51.86	52.07	51.36	49.67	51.31	48.26	48.60	48.26	49.18	46.69	44.15
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,480	1,305	837	591	531	1,034	1,183	1,093	1,030	963	1,140
Invested Capital Turnover	1.35	1.45	2.25	1.90	2.00	1.72	1.96	2.30	2.46	1.92	1.66
Increase / (Decrease) in Invested Capital	-25	-135	-99	-928	-949	-271	345	502	499	-71	-42
Enterprise Value (EV)	1,579	1,237	824	520	794	1,396	1,637	1,492	1,598	1,935	2,037
Market Capitalization	1,067	781	843	635	995	1,127	1,244	1,233	1,459	1,837	1,775
Book Value per Share	$11.53	$10.11	$10.33	$8.40	$8.53	$8.91	$9.19	$9.71	$10.23	$10.08	$10.59
Tangible Book Value per Share	($6.90)	($6.62)	($6.71)	($6.45)	($6.05)	($5.70)	($5.40)	($4.87)	($4.36)	($4.79)	($4.89)
Total Capital	1,605	1,482	953	724	752	1,383	1,402	1,441	1,493	1,463	1,469
Total Debt	637	633	96	18	19	618	613	608	603	597	591
Total Long-Term Debt	622	618	80	0.00	0.00	597	590	584	577	571	398
Net Debt	512	456	-19	-115	-201	269	393	259	139	98	262
Capital Expenditures (CapEx)	9.15	8.35	5.33	6.96	6.29	-1.04	3.32	4.52	5.34	5.29	6.25
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-40	-68	80	3.59	-46	-122	24	-53	-113	-168	7.84
Debt-free Net Working Capital (DFNWC)	85	109	196	137	174	226	243	296	350	331	337
Net Working Capital (NWC)	70	95	179	119	155	205	221	272	325	305	144
Net Nonoperating Expense (NNE)	6.55	46	4.16	43	6.62	5.45	2.96	3.50	-16	2.36	2.14
Net Nonoperating Obligations (NNO)	512	456	-19	-115	-201	269	393	259	139	98	262
Total Depreciation and Amortization (D&A)	9.49	9.29	11	9.03	6.52	7.12	5.56	5.54	5.79	5.87	6.22
Debt-free, Cash-free Net Working Capital to Revenue	-1.97%	-3.43%	4.01%	0.18%	-2.29%	-6.08%	1.19%	-2.71%	-5.88%	-8.79%	0.41%
Debt-free Net Working Capital to Revenue	4.23%	5.49%	9.79%	6.83%	8.69%	11.23%	12.28%	15.24%	18.21%	17.32%	17.44%
Net Working Capital to Revenue	3.48%	4.74%	8.97%	5.95%	7.73%	10.21%	11.16%	14.02%	16.89%	15.92%	7.48%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.26	($1.50)	$0.05	($1.84)	$0.23	$0.37	$0.25	$0.46	$0.85	$0.41	$0.37
Adjusted Weighted Average Basic Shares Outstanding	82.54M	82.20M	82.86M	83.33M	83.89M	83.33M	84.44M	84.80M	84.61M	84.08M	80.88M
Adjusted Diluted Earnings per Share	$0.26	($1.50)	$0.05	($1.84)	$0.23	$0.37	$0.24	$0.46	$0.84	$0.40	$0.36
Adjusted Weighted Average Diluted Shares Outstanding	82.95M	82.20M	83.28M	83.33M	84.52M	83.33M	85.43M	85.53M	85.61M	85.27M	83.08M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	84.02M	84.12M	84.15M	85.87M	85.88M	85.83M	85.91M	87.08M	85.88M	83.00M	82.12M
Normalized Net Operating Profit after Tax (NOPAT)	28	-76	13	27	40	58	29	45	60	40	35
Normalized NOPAT Margin	5.52%	-15.41%	2.54%	5.26%	7.90%	11.46%	6.23%	9.70%	12.27%	8.18%	7.45%
Pre Tax Income Margin	6.09%	-27.97%	1.58%	-33.26%	4.94%	6.63%	6.13%	11.72%	17.81%	9.23%	8.16%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	3.88	-11.06	1.50	-15.30	3.34	4.05	3.51	6.56	7.61	5.58	5.04
NOPAT to Interest Expense	2.69	-7.74	0.77	-10.71	2.57	3.70	2.59	4.68	6.22	4.12	3.84
EBIT Less CapEx to Interest Expense	3.00	-11.89	1.00	-15.98	2.72	4.15	3.14	6.06	7.01	4.98	4.28
NOPAT Less CapEx to Interest Expense	1.81	-8.57	0.27	-11.39	1.95	3.81	2.23	4.19	5.62	3.52	3.08
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	2.55%	-1.52%	-1.46%	-0.41%	-0.42%	-1.72%	-2.90%	2.35%	14.36%	52.41%	61.17%

Financials Breakdown Chart

Key Financial Trends

I analyzed Pediatrix Medical Group (NYSE: MD) using the latest quarterly statements (Q1–Q4 of 2025, plus prior years for context). The focus is on revenue, profitability, cash flow, and balance-sheet trends over the last four years, with a quick read on what this could mean for investors.

Revenue trend in 2025: Operating revenue rose from 458.4 million in Q1 2025 to 493.8 million in Q4 2025, indicating improving topline performance through the year.
Continued quarterly profitability in late 2025: Net income from continuing operations was positive in Q3 2025 (about 71.7 million) and remained positive in Q4 2025 (about 33.7 million), suggesting ongoing profitability even as quarterly mix shifts.
Solid operating cash flow in the latest quarters: Net cash from continuing operating activities was strong in Q3 2025 (about 138.1 million) and remained positive in Q4 2025 (about 114.6 million), highlighting cash-generating operations.
Modest debt levels and stable interest expense: Long-term debt hovered in the mid-to-high 500 millions (roughly 0.58–0.59 billion across 2025), with interest expense typically in the range of 8–10 million per quarter, indicating manageable leverage.
Substantial goodwill and intangible assets: Goodwill around 1.23–1.53 billion and intangible assets in the single-digit millions remain a large non-cash asset base on the balance sheet, reflecting past acquisitions and brand value.
Persistent negative retained earnings: Retained earnings were negative across 2025 quarters (for example, about -116.8 million in Q3 2025, -188.5 million in Q2 2025, and -227.8 million in Q1 2025), signaling a cumulative loss trend and potential future dilution considerations.
Margin pressure from higher operating costs in Q4 2025: SG&A and total operating expenses increased in Q4 2025 (SG&A about 413.7 million; total operating expenses about 444.98 million), contributing to a drop in operating income to about 48.8 million from 68.1 million in Q3 2025.
Quarterly earnings per share (EPS) show volatility: Basic EPS ranged from about 0.25 in Q1 2025 to a high around 0.85 in Q3 2025, then about 0.41 in Q4 2025, reflecting quarterly mix and non-operating items.
Balance-sheet leverage and asset base: Total assets run in the 2.0–2.3 billion range with total liabilities around 1.0–1.4 billion across 2025 quarters, indicating a solid asset base but a modest level of leverage to monitor alongside the large goodwill balance.
Seasonality pattern observed in quarterly results: The data show a stronger earnings/margin profile in Q3 relative to other quarters, with some pullbacks in Q1 and Q4—useful context for expectations around quarterly reporting and guidance.

05/14/26 12:22 PM ETAI Generated. May Contain Errors.

Pediatrix Medical Group Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Pediatrix Medical Group's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Pediatrix Medical Group's net income appears to be on an upward trend, with a most recent value of $165.39 million in 2025, falling from $335.69 million in 2015. The previous period was -$99.07 million in 2024. View Pediatrix Medical Group's forecast to see where analysts expect Pediatrix Medical Group to go next.

Pediatrix Medical Group's total operating income in 2025 was $208.81 million, based on the following breakdown:

Total Gross Profit: $1.91 billion
Total Operating Expenses: $1.71 billion

Over the last 10 years, Pediatrix Medical Group's total revenue changed from $2.78 billion in 2015 to $1.91 billion in 2025, a change of -31.2%.

Pediatrix Medical Group's total liabilities were at $1.38 billion at the end of 2025, a 0.5% decrease from 2024, and a 34.5% decrease since 2015.

In the past 10 years, Pediatrix Medical Group's cash and equivalents has ranged from $9.82 million in 2022 to $1.12 billion in 2020, and is currently $375.24 million as of their latest financial filing in 2025.

Over the last 10 years, Pediatrix Medical Group's book value per share changed from 25.92 in 2015 to 10.08 in 2025, a change of -61.1%.

Related Companies

Financial statements for NYSE:MD last updated on 5/7/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pediatrix Medical Group (MD) Financials

Financials Breakdown Chart

Key Financial Trends

Pediatrix Medical Group Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pediatrix Medical Group (MD) Financials

Annual Income Statements for Pediatrix Medical Group

Quarterly Income Statements for Pediatrix Medical Group

Annual Cash Flow Statements for Pediatrix Medical Group

Quarterly Cash Flow Statements for Pediatrix Medical Group

Annual Balance Sheets for Pediatrix Medical Group

Quarterly Balance Sheets for Pediatrix Medical Group

Annual Metrics And Ratios for Pediatrix Medical Group

Quarterly Metrics And Ratios for Pediatrix Medical Group

Financials Breakdown Chart

Key Financial Trends

Pediatrix Medical Group Financials - Frequently Asked Questions

When does Pediatrix Medical Group's fiscal year end?

How has Pediatrix Medical Group's net income changed over the last 10 years?

What is Pediatrix Medical Group's operating income?

How has Pediatrix Medical Group's revenue changed over the last 10 years?

How much debt does Pediatrix Medical Group have?

How much cash does Pediatrix Medical Group have?

How has Pediatrix Medical Group's book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools